VRCA
NASDAQ
US
Verrica Pharmaceuticals Inc. - Common Stock
$5.47
▼ $-0.02
(-0.36%)
Vol 39K
2
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$78.9M
ROE
-271.4%
Margin
-84.4%
D/E
3003.18
Beta
1.49
52W
$3–$10
Wall Street Consensus
11 analysts · Apr 20263
Strong Buy
6
Buy
2
Hold
0
Sell
0
Strong Sell
81.8%
Buy Rating
Price Chart
Similar Stocks
ASRT
Assertio Holdings Inc
$58.2M
ANTX
AN2 Therapeutics Inc
$31.2M
LONA
LeonaBio Inc
TTRX
Turn Therapeutics Inc
AARD
Aardvark Therapeutics Inc
$285.8M
RANI
Rani Therapeutics Holdings Inc
$164.1M
PLRX
Pliant Therapeutics Inc
$75.0M
GRCE
Grace Therapeutics, Inc
$53.5M
CGTX
Cognition Therapeutics Inc
$119.2M
Earnings
Beat rate: 75.0%
Next Report
May 11, 2026
EPS Estimate: $-0.48
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.48 | — | — |
| Dec 2025 | $-0.81 | $-0.46 | +$0.35 |
| Sep 2025 | $-0.69 | $-0.03 | +$0.66 |
| Jun 2025 | $-0.72 | $0.02 | +$0.74 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | — | -271.4% | -271.4% | -271.4% | -271.4% | -271.4% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | 1.6% | -481.4% | -156.1% | -156.1% | -156.1% | -84.4% |
| Gross Margin | 96.1% | 82.1% | 90.6% | 90.6% | 90.6% | 91.4% |
| D/E Ratio | — | 3003.18 | 3003.18 | 3003.18 | 3003.18 | 3003.18 |
| Current Ratio | 1.26 | 1.34 | 1.26 | 1.26 | 1.26 | 1.25 |
Key Ratios
ROA (TTM)
-59.0%
P/S (TTM)
2.56
P/B
15.6
EPS (TTM)
$-3.44
CF/Share
$-1.08
Rev Growth 3Y
-14.3%
52W High
$9.82
52W Low
$3.28
$3.28
52-Week Range
$9.82
How does VRCA compare to Pharmaceuticals peers?
Peer group: Micro-cap Pharmaceuticals (All) · 171 companies
VRCA valuation vs Pharmaceuticals peers
P/E ratio
—
▼
0%
below
peers
(22.4)
vs Peers
vs Industry
Undervalued
P/S ratio
2.6
▼
48%
below
peers
(5.0)
vs Peers
vs Industry
Undervalued
P/B ratio
15.6
▲
635%
above
peers
(2.1)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(2.0%)
vs Peers
vs Industry
Low yield
VRCA profitability vs Pharmaceuticals peers
ROE
-271.4%
▼
400%
below
peers
(-54.3%)
vs Peers
vs Industry
Weak
Net margin
-84.4%
▼
78%
below
peers
(-47.4%)
vs Peers
vs Industry
Weak
Gross margin
91.4%
▲
34%
above
peers
(68.3%)
vs Peers
vs Industry
Below avg
ROA
-59.0%
▼
58%
below
peers
(-37.4%)
vs Peers
vs Industry
Weak
VRCA financial health vs Pharmaceuticals peers
D/E ratio
3003.2
▲
194912%
above
peers
(1.5)
vs Peers
vs Industry
High debt
Current ratio
1.3
▼
63%
below
peers
(3.4)
vs Peers
vs Industry
Low liquidity
Beta
1.5
▲
58%
above
peers
(0.9)
vs Peers
vs Industry
More volatile
VRCA fundamentals radar
VRCA
Peer median
Industry
VRCA profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
VRCA vs peers: key metrics
Latest News
No related news yet